samatasvir
Sign in to saveSamatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 884.313823
Show 4 more facts
- isomeric SMILES
- CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC5=C(S4)C=C(S5)C6=CC7=C(C=C6)N=C(N7)[C@@H]8CCCN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)NC(=O)OC
- chemical formula
- C₄₇H₄₈N₈O₆S₂
- canonical SMILES
- CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC5=C(S4)C=C(S5)C6=CC7=C(C=C6)N=C(N7)C8CCCN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)NC(=O)OC
- Commons category
- Samatasvir
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.
Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex. While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.
Excerpted from Wikipedia’s “samatasvir” article, available under the CC BY-SA 4.0 licence.